Details of the Drug Pharmacogenomic Perturbation Atlas

EUGENOL Drug Info

eugenol; 97-53-0; 4-Allyl-2-methoxyphenol; 4-Allylguaiacol; Eugenic acid; Allylguaiacol; Caryophyllic acid; p-Allylguaiacol; p-Eugenol; 2-Methoxy-4-prop-2-enylphenol; Engenol; 2-Methoxy-4-allylphenol; Phenol, 2-methoxy-4-(2-propenyl)-; 1,3,4-Eugenol; 4-Allylcatechol-2-methyl ether; Synthetic eugenol; 2-Methoxy-4-(2-propenyl)phenol; 2-Methoxy-1-hydroxy-4-allylbenzene; 4-Allyl-1-hydroxy-2-methoxybenzene; 1-Hydroxy-2-methoxy-4-allylbenzene; 5-Allylguaiacol; 1-Hydroxy-2-methoxy-4-prop-2-enylbenzene

Cross-matching ID

PubChem CID

3314

ChEBI ID

CHEMBL42710

CAS Number

CAS 97-53-0

TTD Drug ID

D0O4QB

INTEDE Drug ID

DR1942

General Information of Drug (ID: DM7US1H)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.45	0.00e+0	34/36 (94.44%)	PCNA;MCM2;MCM3;...
Mismatch repair	2.18	0.00e+0	22/23 (95.65%)	PCNA;MSH2;RPA3;...
Pyrimidine metabolism	2.18	0.00e+0	40/56 (71.43%)	RRM2;TYMS;DUT;...
Cell cycle	2.16	0.00e+0	110/124 (88.71%)	E2F2;PCNA;CDK1;...
Fanconi anemia pathway	2.07	1.41e-3	36/54 (66.67%)	FANCI;RPA3;CENPX;...
Base excision repair	1.96	1.17e-3	29/33 (87.88%)	PCNA;FEN1;POLE2;...
Oxidative phosphorylation	1.91	6.03e-3	93/133 (69.92%)	NDUFB2;PPA1;NDUFAB1;...
Proximal tubule bicarbonate reclamation	1.90	7.03e-3	21/23 (91.3%)	CA2;CA4;SLC4A4;...
Aminoacyl-tRNA biosynthesis	1.89	7.03e-3	15/66 (22.73%)	IARS2;CARS2;NARS2;...
Ribosome biogenesis in eukaryotes	1.89	7.03e-3	52/108 (48.15%)	IMP3;NXT1;NXT2;...
Cysteine and methionine metabolism	1.85	9.59e-3	43/50 (86%)	ADI1;CTH;PSAT1;...
Citrate cycle (TCA cycle)	1.80	1.70e-2	30/30 (100%)	IDH3A;FH;SUCLG2;...
RNA transport	1.77	1.73e-2	128/186 (68.82%)	TARDBP;NXT1;DDX19A;...
Purine metabolism	1.76	1.61e-2	102/129 (79.07%)	RRM2;ADCY1;PKM;...
RNA degradation	1.75	1.83e-2	53/79 (67.09%)	BTG3;PFKL;TENT4A;...
Glycolysis / Gluconeogenesis	1.63	4.61e-2	56/67 (83.58%)	PGAM1;PFKL;PKM;...
Proteasome	1.63	4.38e-2	44/46 (95.65%)	PSMB10;PSMA6;PSMA7;...
Graft-versus-host disease	-1.77	1.05e-2	32/42 (76.19%)	HLA-E;HLA-B;HLA-DQA1;...
Phagosome	-1.77	1.08e-2	118/152 (77.63%)	RAB5C;ATP6V0A1;MRC2;...
Legionellosis	-1.77	1.11e-2	51/57 (89.47%)	PYCARD;HSPA1A;MYD88;...
B cell receptor signaling pathway	-1.78	1.06e-2	71/81 (87.65%)	INPPL1;PIK3R1;DAPP1;...
Neurotrophin signaling pathway	-1.78	1.10e-2	107/119 (89.92%)	SH2B3;FASLG;MAPK7;...
Th17 cell differentiation	-1.79	1.14e-2	95/107 (88.79%)	ZAP70;RXRB;STAT6;...
Salmonella infection	-1.83	9.58e-3	198/249 (79.52%)	GAPDH;RHOG;MAPK8;...
ErbB signaling pathway	-1.87	7.22e-3	79/85 (92.94%)	AKT3;GAB1;BRAF;...
Leishmaniasis	-1.89	6.39e-3	67/77 (87.01%)	MYD88;MAPK14;ITGAM;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.89	6.69e-3	79/89 (88.76%)	ZAP70;PIK3R1;PRKCQ;...
Estrogen signaling pathway	-1.89	7.03e-3	119/137 (86.86%)	SOS1;NCOA1;CREB3L1;...
T cell receptor signaling pathway	-1.92	4.71e-3	93/104 (89.42%)	ZAP70;PIK3R1;PRKCQ;...
TNF signaling pathway	-1.92	4.26e-3	103/112 (91.96%)	MAPK8;TRADD;MAPK14;...
C-type lectin receptor signaling pathway	-1.93	3.76e-3	93/104 (89.42%)	MAPK8;PYCARD;IRF9;...
Lipid and atherosclerosis	-1.98	2.40e-3	190/215 (88.37%)	MAPK8;NOX1;PYCARD;...
Amoebiasis	-1.99	2.55e-3	99/102 (97.06%)	COL3A1;LAMB3;ACTN1;...
Natural killer cell mediated cytotoxicity	-2.02	9.12e-4	99/131 (75.57%)	IFNA21;KIR2DL3;CD48;...
Yersinia infection	-2.03	9.83e-4	120/137 (87.59%)	RHOG;MAPK8;RPS6KA1;...
Tuberculosis	-2.03	1.06e-3	159/180 (88.33%)	MAPK8;RAB5C;ITGAX;...
NF-kappa B signaling pathway	-2.07	1.16e-3	90/104 (86.54%)	ERC1;TRADD;MYD88;...
Shigellosis	-2.10	1.28e-3	180/246 (73.17%)	MYL10;PRKCQ;TNIP1;...
IL-17 signaling pathway	-2.12	1.42e-3	84/94 (89.36%)	MAPK8;TRAF3IP2;TRADD;...
NOD-like receptor signaling pathway	-2.16	0.00e+0	145/181 (80.11%)	ATG5;MAPK8;SHARPIN;...
Rheumatoid arthritis	-2.18	0.00e+0	78/93 (83.87%)	ATP6V1G1;HLA-DQA1;CD86;...
Retinol metabolism	-2.19	0.00e+0	41/68 (60.29%)	RDH11;RDH16;CYP26A1;...
Staphylococcus aureus infection	-2.22	0.00e+0	72/95 (75.79%)	KRT9;KRT18;ITGAM;...
Osteoclast differentiation	-2.24	0.00e+0	117/127 (92.13%)	AKT3;IFNGR2;LILRB4;...
Pertussis	-2.25	0.00e+0	64/76 (84.21%)	GNAI3;MAPK8;PYCARD;...
Epithelial cell signaling in Helicobacter pylori infect...	-2.28	0.00e+0	62/70 (88.57%)	ATP6V0C;PLCG1;ATP6V1E1;...
Pathogenic Escherichia coli infection	-2.28	0.00e+0	152/197 (77.16%)	MYO1E;NCKAP1L;TLR5;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	1.25uM - 40uM	3H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H